case_images: PMC10687936_01
case_images: Clinical findings prior to treatment with deucravacitinib. (a) illustrates alopecia areata (AA) over the vertex of the scalp. (b) illustrates AA over the occiput of the scalp.
case_images: 10.1177_2050313X231213135-fig1.jpg
case_images: PMC10687936_01_10.1177_2050313X231213135-fig1.jpg
case_images: fig1-2050313X231213135
case_images: In September 2021, the SALT score was 97, with complete loss of bilateral eyebrows and eyelashes and almost complete loss of body hair (Figure 1).
case_images: Clinical findings 6 weeks after initiating deucravacitinib. (a) illustrates regrowth of short white-gray hairs along the occipital region of the scalp. (b) illustrates regrowth of eyebrow hairs and eyelashes, with some dark hairs in the eyebrows.
case_images: 10.1177_2050313X231213135-fig2.jpg
case_images: PMC10687936_01_10.1177_2050313X231213135-fig2.jpg
case_images: fig2-2050313X231213135
case_images: Short ~1 cm white-gray hairs were noted on the scalp with a SALT score of 45.2 (Figure 2).